Multiple Sclerosis
Conference Recap
Disease-Modifying Therapies in Progressive Multiple Sclerosis
Key presentations at CMSC 2022 included use of BTK inhibitors in MS, results from the DISCOMS trial, and immune response of MS patients vaccinated...
From the Journals
COVID vaccination in DMT-treated MS patients: New data
Conference Coverage
Risk of drug interactions is on the rise as MS drugs evolve
Newer medications pose more danger, pharmacist says, and require more awareness.
Conference Coverage
Consider the wider picture in relapsing remitting MS
The best medication for a patient may not have highest efficacy, one expert says.
Conference Coverage
MS and family planning: Bring it up at every office visit
It’s crucial to counsel women of child-bearing age about options and facts regarding pregnancy, neurologist says.
Conference Coverage
Inebilizumab beneficial across genotypes in NMOSD
"These data illustrate how mechanistic precision in treatment design can help patients gain benefit from their regimen regardless of the genetic...
Conference Coverage
Stem cell transplants for MS are a ‘reasonable option,’ but questions persist
Costly procedures help some patients but where to draw the line is unclear.
Conference Coverage
MS and COVID-19: Conflicting signs on risk but some trends are clearer
Patients on certain DMTs seem to fare worse and careful timing of vaccination is advisable.
Conference Coverage
Non-White subjects are sparse in DMT trials for MS
Black people only made up 1.9% of participants in studies reporting full racial data over 25 years.
Latest News
B-cell level may affect COVID booster efficacy in MS
“It’s meaningless to just go by some recommendation covering time since the last treatment.”
Feature
Abortion debate may affect Rx decisions for pregnant women
Enactment of abortion restrictions in a growing number of states could have a chilling effect on therapy regimens in pregnant women and their...